Market research
9OM1.F EXMceuticals Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 10M
- P/E ratio
- 0.32
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.52
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- CA30207T1049
- Market cap
- 10M
- P/E ratio
- 0.32
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.52
About
About EXMceuticals Inc
EXMceuticals Inc. engages in the production of cannabinoid formulations. The company primarily focuses around the matching of natural bioactive ingredients extracted from the cannabis plant with the needs of the nutraceutical, cosmeceutical, therapeutic, and pharmaceutical industries. It focuses on the production of CBD, a non-psychoactive cannabinoid that has been proven effective against acne, anxiety, depression, epilepsy, and degenerative diseases, such as Parkinson's; and THC, a psychoactive cannabinoid ingredient that has been proven effective in the fields of pain management, appetite control, anxiety, and managing side effects of chemotherapy. The company was incorporated in 2008 and is headquartered in Quebec, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 9OM1.F discussion.
5 years, 5 months ago
EXMceuticals Inc is currently in a long term uptrend where the price is trading 4.0% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
EXMceuticals Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 7.2% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 71.8% to $-368K since the same quarter in the previous year.
Based on the above factors, EXMceuticals Inc gets an overall score of 3/5.